Anxiety News and Research

Latest Anxiety News and Research

Final results of SAPHRIS clinical study released

Schering-Plough Corporation today reported final results of a SAPHRIS(R) (asenapine) long-term schizophrenia relapse prevention clinical study.

14 Sep 2009

Campaign for prevention and control of head lice

The National Association of School Nurses (NASN) announced today the kickoff of S.C.R.A.T.C.H. (School and Community Resources to Avoid and Take Control of Head Lice), a campaign to educate school nurses, students, parents and the general public about the prevention and control of head lice.

14 Sep 2009

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

ISENTRESS , an integrase inhibitor from Merck & Co., Inc., was studied in comparison to efavirenz in maintaining viral load suppression to undetectable levels (less than 50 copies/mL) and at improving CD4 cell counts in previously untreated (treatment-naïve) HIV-1-infected patients through 96 weeks in a Phase III study called STARTMRK.

14 Sep 2009

Results further support the benefits of TYSABRI for multiple sclerosis patients

Biogen Idec and Elan Corporation, plc (NYSE: ELN) today announced six-month results of an ongoing, one-year longitudinal, observational, patient-reported outcomes study showing multiple sclerosis (MS) patients taking TYSABRI- (natalizumab) experienced an improvement in both their physical function and psychological well-being.

14 Sep 2009

Scientific program to treat and prevent mental disorders

Mental disorders are a global problem and represent one of the biggest challenges for health care systems. In the world, there are some 500 million people suffering from mental disorders, and in the European Union, mental disorders range as one of the leading causes of disease burden.

14 Sep 2009

Phase 2 MS clinical trial data continues to show durable reductions in relapse rate

Genzyme Corporation reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab.

14 Sep 2009

Monoamine oxidases responsible for personality and behaviour

Antisocial and aggressive behaviours represent a widespread and expensive social problem. Recent research has convincingly shown that there is a strong interaction between genetic inheritance and environment for development of personality and behaviour.

14 Sep 2009

Cymbalta maintains reduction in pain for patients with chronic low back pain

New data show patients with chronic low back pain on Cymbalta(R) (duloxetine HCl) maintained reductions in pain for 41 weeks. In patients who initially responded to duloxetine, this maintenance of pain reduction was accompanied by further reduction in pain that was statistically significant as measured by the Brief Pain Inventory (BPI) average pain rating.

11 Sep 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

Low self-esteem in children may lead to adult obesity

Previous research has shown that low self-esteem and emotional problems are found in people who are overweight or obese- but not which influences which. Research published today in the open access journal BMC Medicine, sheds light on this issue showing that children with emotional difficulties are at higher risk for obesity in adult life.

11 Sep 2009

Depression and substance dependency may be more common among people

The prevalence of anxiety, depression and substance dependency may be twice as high as the mental health community has been led to believe.

10 Sep 2009

Teva's COPAXONE holds promise for relapsing remitting multiple sclerosis

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today presented data that demonstrated patients treated for 10 and 15 years with COPAXONE® (glatiramer acetate injection) had significant reduction in disease severity. These data, generated from the longest continuous prospective study of any disease modifying therapy in relapsing remitting multiple sclerosis (RRMS), were presented today at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany.

10 Sep 2009

First edition: September 10, 2009

In response to President Obama's joint address to Congress last night, the headlines are chock full of news, analysis, fact-checkers and inventories of cheers and jeers.

10 Sep 2009

Season's Practice launches women health and wellness solutions in Northeast Ohio

Season's Practice has opened its doors to women in Northeast Ohio who are seeking alternative health and wellness solutions to improve their overall health and well-being.

10 Sep 2009

New protocol to tackle postpartum depression

Up to 80 percent of women experience depressive symptoms postpartum, with one in eight reporting the emergence of major depression within weeks of delivery.

10 Sep 2009

Psychological suffering crosses species lines, according to a study

A recent study documents the severe emotional trauma chimpanzees suffer as a result of laboratory use and confinement. Developmental Context Effects on Bicultural Post-Trauma Self Repair in Chimpanzees was published in the September issue, Vol. 45 (5), of the American Psychological Association journal Developmental Psychology.

9 Sep 2009

Mentally ill smokers also benefit from treatment, says research paper

People with mental illnesses such as depression and anxiety are the heaviest smokers in the country, but their doctors are afraid to ask them to quit. They assume that if their patients try to quit smoking, their mental disorders will get worse.

9 Sep 2009

Disposable Grind-No-More dental night protector launched by Plackers

Plackers(R), makers of the first disposable dental flosser, expands its line of convenient home dental care products with the Grind-No-More(R) Night Protector, the first disposable, ready-to-use night protector on the market that combats bruxism, commonly known as teeth grinding.

9 Sep 2009

School bullying and violence prevention programs

Key to a child's successful education is an environment in which he or she can learn safely. According to a report released today by the C.S. Mott Children's Hospital National Poll on Children's Health, only 26 percent of parents would give their child's high school an "A" for preventing bullying and school violence, and 38 percent of parents would give their child's elementary or junior high an "A."

9 Sep 2009